[Skip to Content]
[Skip to Content Landing]
Citations 0
Quick Uptakes
February 23, 2000

Copper and Cancer

Author Affiliations

Not Available

Not Available

JAMA. 2000;283(8):994. doi:10.1001/jama.283.8.994-JQU00000-3-1

Depriving malignant tumors of their copper supply may be a potent antiangiogenesis strategy for stabilizing patients with advanced cancer.

In last month's Clinical Cancer Research, investigators at the University of Michigan Medical School described a surprise finding from a clinical trial designed to determine how well tetrathiomolybdate (TM), an inexpensive compound, could lower copper levels in patients with cancer. In five of six patients kept at 20% of normal copper levels for more than 90 days, existing tumors did not grow and new tumors did not form for more than 1 year. Another 12 patients could not achieve or maintain the target copper level for 90 days because of disease progression.

First Page Preview View Large
First page PDF preview
First page PDF preview